Expression of the TRPV1 receptor differs in quiescent inflammatory bowel disease with or without abdominal pain
- Ayesha Akbar1,
- Yiangos Yiangou2,
- Paul Facer2,
- W G Brydon3,
- Julian R F Walters1,
- Praveen Anand2,
- Subrata Ghosh4
- 1Department of Gastroenterology, Imperial College London, UK
- 2Department of Clinical Neuroscience, Imperial College London, UK
- 3Department of Clinical Biochemistry, Western General Hospital, Edinburgh, UK
- 4Division of Gastroenterology, University of Calgary, Alberta, Canada
- Correspondence to Professor Subrata Ghosh, Division of Gastroenterology, University of Calgary, Alberta, Canada;
- Revised 24 January 2010
- Accepted 25 January 2010
Objective Transient receptor potential vanilloid type 1 (TRPV1) has been shown to play an important role in visceral hypersensitivity. A significant proportion of patients with inflammatory bowel disease (IBD) continue to complain of abdominal pain despite their disease being otherwise quiescent. We investigated TRPV1-immunoreactive fibres in rectosigmoid biopsies taken from such patients with correlation to abdominal pain severity.
Methods Rectosigmoid biopsies were collected from 20 patients with quiescent IBD fulfilling Rome II criteria for irritable bowel syndrome (IBS), from 20 asymptomatic patients with quiescent IBD and from 28 controls. Abdominal pain scores were recorded using a validated questionnaire. TRPV1- and neuronal marker protein gene product 9.5 (PGP 9.5)-expressing nerve fibres, and lymphocytes (CD3 and CD4) were quantified, following immunohistochemistry with specific antibodies. The biopsy findings were related to abdominal pain scores.
Results A significant 3.9-fold increase in median number of TRPV1-immunoreactive fibres was found in biopsies from patients with quiescent IBD with IBS symptoms when compared with controls (p<0.0001) and a 5-fold increase when compared with the asymptomatic quiescent IBD group (p=0.0003). In the IBD with IBS symptoms group, the total nerve fibres (PGP 9.5) did not differ from those in the asymptomatic IBD group (p=0.10) or the control group (p=0.33) and neither did the CD3 lymphocyte (asymptomatic IBD group p=0.17; controls p=0.88) or CD4 lymphocyte (asymptomatic IBD group p=0.39; controls p=0.97) counts. In stepwise multivariate linear regression analysis, only TRPV1-immunoreactive nerve fibres (R2=0.8; p<0.0001) were significantly related to the abdominal pain score.
Conclusions Increased TRPV1 nerve fibres are seen in quiescent IBD with IBS-like symptoms together with a correlation to pain severity. TRPV1 may contribute to the pathophysiology of ongoing pain and visceral hypersensitivity in this group of patients, providing a potential therapeutic target.
- Abdominal pain
- health-related quality of life
- inflammatory bowel disease (IBD)
- transient receptor potential vanilloid type-1 (TRPV-1)
- visceral hypersensitivity
Funding National Association of Colitis and Crohn's disease, GSK via Imperial College ADI.
Competing interests None.
Patient consent Obtained.
Ethics approval This study was conducted with the approval of the Hammersmith Research Ethics Committee.
Provenance and peer review Not commissioned; externally peer reviewed.